Signatures of mutational processes in human cancer
By Ludmil B. Alexandrov, S. Nik-Zainal, David C. Wedge, S. Aparicio, Sam Behjati, A. Biankin, G. Bignell, N. Bolli, Å. Borg, A. Børresen-Dale and 60 more. Nature, 2013
9,146 citations recorded by the source corpus.
All cancers are caused by somatic mutations; however, understanding of the biological processes generating these mutations is limited. The catalogue of somatic mutations from a cancer genome bears the signatures of the mutational processes that have been operative. Here we analysed 4,938,362 mutations from 7,042 cancers and extracted more than 20 distinct mutational signatures. Some are present in many cancer types, notably a signature attributed to the APOBEC family of cytidine deaminases, whereas others are confined to a single cancer class. Certain signatures are associated with age of the patient at cancer diagnosis, known mutagenic exposures or defects in DNA maintenance, but many are of cryptic origin. In addition to these genome-wide mutational signatures, hypermutation localized to small genomic regions, ‘kataegis’, is found in many cancer types. The results reveal the diversity of mutational processes underlying the development of cancer, with potential implications for understanding of cancer aetiology, prevention and therapy.
Subfields: Cancer Research, Molecular Biology, Pathology and Forensic Medicine
View Paper: https://www.semanticscholar.org/paper/42209e55d43cb46512026fa3cec380e04d977b4f
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Cancer Research
- Nicholas McGranahan
- Charles Swanton
- Gad Getz
- Casey S. Greene
- G. Way
- Shun Liu
- Elaine R. Mardis
- Oliver Stegle
In Molecular Biology
- Peter W. Laird
- Nicholas McGranahan
- Charles Swanton
- Eric S. Lander
- S. Baylin
- Hui Shen
- Wanding Zhou
- Elaine R. Mardis
In Pathology and Forensic Medicine
- A. D’Andrea
- Raphael Ceccaldi
- H. B. EL‐SERAG
- John N. Weinstein
- James P. Allison
- Padmanee Sharma
- Peter W. Laird
- David Haussler
Citations in the corpus
- Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers (2017, background): “NSCLC, which are both tumors with a high tumor mutational burden (TMB) (17).”
- OncodriveFML: a general framework to identify coding and non-coding regions with cancer driver mutations (2016, methodology): “…and 3 ′ UTR regions of coding genes containing mutations across 22 tumor cohorts with whole-genome data sequenced by TCGA [12] or other projects [20] (datasets WG-505 and WG-608, respectively, in Additional file 1), as well as two pan-cancer cohorts resulting from pooling the mutations detected…”
- Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden (2017, background): “Mutations in a number of other genes have also been linked to increased TMB [28, 51], but their function is less well understood.”
- Genomic basis for RNA alterations in cancer (2020, methodology): “Global variations in mutational patterns can be quantified using mutational signatures, which tag mutational processes specific to their tissue-of-origin and environmental exposures 19 .”